Skip to main content
. 2019 Nov 6;10:1311. doi: 10.3389/fphar.2019.01311

Figure 2.

Figure 2

WZB117 may enhance the growth inhibitory effect of MK-2206 via inhibition of GLUT1 in MCF-7 and MDA-MB-231 cells. (A) WZB117 inhibits glucose uptake in MCF-7 and MDA-MB-231 cells. Cells were incubated with 2-NBDG in the presence of DMSO, 6 µM MK-2206 and/or 60 µM WZB117 (MCF-7) or 12 µM MK-2206 and/or 60 µM WZB117 (MDA-MB-231) for 1.5 h and harvested for flow cytometric analysis of 2-NBDG fluorescence, and relative 2-NBDG uptake was calculated. Data are presented as the mean ± SEM of three independent experiments. (B) Knockdown of GLUT1 enhances the growth inhibitory effect of MK-2206 in MCF-7 and MDA-MB-231 cells. Cells were transfected with control siRNA (siCTL) or GLUT1 siRNA (siGLUT1) and then treated with MK-2206 (6 µM in MCF-7 cells or 12 µM in MDA-MB-231 cells) for 72 h, followed by the MTT assay to assess cell viability. Data are presented as the mean ± SEM of three independent experiments. (C) Western blot analysis of GLUT1 in MCF-7 cells after siRNA transfection and MK-2206 treatment. MCF-7 cells were transfected with control siRNA (siCTL) or GLUT1 siRNA (siGLUT1), allowed to recover for 48 h, and then treated with 6 µM MK-2206 for 48 h before harvested for Western blot analysis. *** P < 0.001, n.s., not significant (P > 0.05).